Market Overview

Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential

Share:
Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential

According to reports on CNBC and the Wall Street Journal, several companies, including Allergan plc Ordinary Shares (NYSE: AGN) and Merck & Co., Inc. (NYSE: MRK), have expressed an interest in acquiring Biogen Inc (NASDAQ: BIIB).

Credit Suisse’s Alethia Young maintained a Neutral rating on the company, with a price target of $322.

Potential Value

“Based on our M&A DCF for Biogen, we project potential values of ~$370/share to $410/share,” Young mentioned.

The analyst explained that the potential values were derived using the R&D, SG&A and tax rates for Allergan and Merck, although there still was uncertainty regarding whether a deal would actually occur.

Why Is Biogen Attractive?

Young believes that some of the pipeline and clinical expertise aspects that make Biogen attractive as an acquisition target include the company’s Alzheimer’s franchise, robust clinical infrastructure and expertise in Cambridge, the SMA platform and the multiple sclerosis base business.

“From a Biogen perspective, we think there are significant expenses that could be removed from their operating model: Biogen's MS sales force is more aligned by product, so we would guess some sales people could sell multiple products,” Young stated.

The analyst estimates that Allergan might reduce R&D and SG&A by 10 percent and 25 percent, respectively.

Young believes that Allergan is likely to benefit from Biogen’s science infrastructure.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2019MaintainsHold
Jun 2019DowngradesOverweightNeutral
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Alethia Young Credit SuisseAnalyst Color M&A News Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (BIIB + AGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LPSNMaintains45.0
DISMaintains140.0
DEReiterates175.0
AMWDMaintains92.0
FTDRMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Citi On Etsy: Looks Like Ashton Kutcher Bought More Than A $100 Ring

Attention Luxury Investors: Kate Spade Just Reported Q2 Results